CAR-T CELL THERAPY FOR FOLLICULAR LYMPHOMAS by Ugo Testa, Francesco D'Alò, Elvira Pelosi, Germana Castelli, Giuseppe Leone

“…The treatment of follicular lymphoma patients with multiply relapsed or refractory disease represents an area of high-unmet needing new treatments with stronger efficacy. Chimeric antigen receptor (CAR)-T cell therapy targeting B-cell antigens, such as CD19 or CD20, is emerging as an efficacious treatment for R/R follicular lymphoma patients, particularly for those with early relapse and refractory to alkylating agents and to anti-CD20 monoclonal antibodies, resulting in a high rate of durable responses in a high proportion of patients.   …”
Get full text

New developments in immunotherapy for SCLC by Zhonglin Hao, Tsering Dolkar, Christopher Gates, Reinhold Munker

“…Three emerging therapeutic options include bispecific T cell engagers targeting DLL3, chimeric antigen receptor T cells (CAR-T cells), and antibody–drug conjugates. …”
Get full text

Current developments in personalized treatment strategies for elderly acute myelogenous leukemia patients by Xueting Hou, Jizhang Bao

“…Acute myelogenous leukemia(AML) is a life-threatening hematologic malignancy that predominantly affects the elderly.Currently, chemotherapy and hematopoietic stem cell transplantation are the primary treatment modalities for AML, though their clinical application is limited in older patients.Recent years have seen the development of novel molecular targeted therapies, such as isocitrate dehydrogenase 1/2 (IDH1/2) and Feline macrophage stimulator-like tyrosine kinase 3 (FLT3) inhibitors, as well as individualized approaches like chimeric antigen receptor T-cell (CAR-T) therapy.However, due to patient heterogeneity and drug resistance, treatment outcomes for elderly AML remain unsatisfactory, underscoring the need for more precise and safer individualized treatment strategies.The combination of chemotherapy with novel targeted or immunotherapies shows promise as a future treatment direction.This research reviews the latest advances in the treatment of elderly AML, with a focus on achieving more individualized and safer therapeutic approaches.…”
Get full text

Application of Bionanomaterials in Tumor Immune Microenvironment Therapy by Jiawei Wang, Yan Bao, Yandan Yao

“…Immune checkpoint blockade therapy and chimeric antigen receptor T-cell (CAR-T) immunotherapy are clinically effective in a variety of cancers. …”
Get full text

The Metabolic Features of Tumor-Associated Macrophages: Opportunities for Immunotherapy? by Sonja S. Mojsilovic, Slavko Mojsilovic, Victor H. Villar, Juan F. Santibanez

“…Also, new macrophage-based cell therapeutic technologies recently developed using chimeric antigen receptor bioengineering are exposed, which may overcome all solid tumor physical barriers impeding the current adoptive cell therapies and contribute to developing novel cancer immunotherapies.…”
Get full text

Identification of a Patient Suitable for CAR-T Cell Therapy in the Outpatient Setting: A Vodcast and Case Example by Ronan Foley, John Kuruvilla

“…Abstract Chimeric antigen receptor T cell (CAR-T) therapies targeting the CD19 antigen have been associated with high and durable response rates in patients with diffuse large B cell lymphoma (DLBCL). …”
Get full text

CAR-T CELL THERAPY FOR T-CELL MALIGNANCIES by Ugo Testa, Patrizia Chiusolo, Elvira Pelosi, Germana Castelli, Giuseppe Leone

“… Chimeric antigen receptor T-cell (CAR-T) therapy has revolutionized the treatment of B-cell lymphoid neoplasia and, in some instances, improved disease outcomes. …”
Get full text

CAR-T CELLS IN CHRONIC LYMPHOCYTIC LEUKEMIA by Ugo Testa, Elvira Pelosi, Germana Castelli, Alberto Fresa, Luca Laurenti

“…Among these new treatments, a potentially curative approach consists of the use of chimeric antigen receptor T (CAR-T) cell therapy, which achieved remarkable success in various B-cell malignancies, including B-cell Non-Hodgkin Lymphomas (NHLs) and B-acute lymphoblastic Leukemia (ALL). …”
Get full text

Bispecific antibody-mediated redirection of NKG2D-CAR natural killer cells facilitates dual targeting and enhances antitumor activity by Congcong Zhang, Anja Waldmann, Winfried S Wels, Jasmin Röder, Anne Scherer, Malena Bodden, Jordi Pfeifer Serrahima, Anita Bhatti, Nina Müller, Pranav Oberoi

“…Furthermore, NKAB-ErbB2 synergized with NK-92 cells or primary T cells engineered to express an NKG2D-CD3ζ chimeric antigen receptor (NKAR), leading to targeted cell killing and greatly enhanced antitumor activity, which remained unaffected by soluble MICA known as an inhibitor of NKG2D-mediated natural cytotoxicity. …”
Get full text

Novel research model for in vitro immunotherapy: co-culturing tumor organoids with peripheral blood mononuclear cells by Peng Li, Minli Huang, Yifan Ma, Yongbin Zhang, Changhong Shi

“…This model stands as a robust instrument for dissecting the TME, elucidating the molecular interactions, and exploring the therapeutic applications of chimeric antigen receptor (CAR)-engineered lymphocytes, as well as other cancer treatment modalities. …”
Get full text

The success of the tumor immunotherapy: neutrophils from bench to beside by Meng Zhu, Ru Jia, Xiaojie Zhang, Pingwei Xu

“…The present immune therapy was focused on the immune checkpoint blockade or Chimeric Antigen Receptor T-Cell Immunotherapy (CART) transfer, but how to activate the innate immune system to antitumor still lags out. …”
Get full text

Immunotherapy Deriving from CAR-T Cell Treatment in Autoimmune Diseases by Yuehong Chen, Jianhong Sun, Huan Liu, Geng Yin, Qibing Xie

“…Chimeric antigen receptor T (CAR-T) cells are T cells engineered to express specific synthetic antigen receptors that can recognize antigens expressed by tumor cells, which after the binding of these antigens to the receptors are eliminated, and have been adopted to treat several kinds of malignancies. …”
Get full text

Combination of AAV-CCL19 and GPC3 CAR-T Cells in the Treatment of Hepatocellular Carcinoma by Min Meng, Yi-chen Wu

“…Background. Chimeric antigen receptor-modified T cell (CAR-T) therapy has great potential for treating malignant tumors, especially hematological malignancies. …”
Get full text

Toll-Like Receptor-Based Strategies for Cancer Immunotherapy by Saghar Pahlavanneshan, Ali Sayadmanesh, Hamidreza Ebrahimiyan, Mohsen Basiri

“…These strategies include systemic administration of TLR antagonist along with immune cell transfer and also genetic engineering of the immune cells using TLR signaling components to improve the function of genetically engineered immune cells such as chimeric antigen receptor-modified T cells. Here, we explore the current status of the cancer immunotherapy approaches based on manipulation of TLR signaling to provide a perspective of the underlying rationales and potential clinical applications. …”
Get full text

Current status and innovative developments of CAR-T-cell therapy for the treatment of breast cancer by Hany E. Marei, Khaled Bedair, Anwarul Hasan, Layla Al-Mansoori, Sara Caratelli, Giuseppe Sconocchia, Alice Gaiba, Carlo Cenciarelli

“…The T cell-based immunotherapy known as chimeric antigen receptor (CAR) T cell treatment, which uses the patient’s immune cells to fight cancer, has demonstrated remarkable efficacy in treating hematologic malignancies; nevertheless, the treatment effects in solid tumors, like breast cancer, have not lived up to expectations. …”
Get full text

CAR-T cell therapy in developing countries: how long should we wait? by Om P Kurmi, Ramila Shilpakar, Sanjivan Gautam, Balram Gautam, Sudhamshu K C

“…However, the survival rates for patients with cancer in these regions are notably lower than those in high-income countries, primarily due to late diagnosis and limited access to advanced treatments. Chimeric antigen receptor (CAR) T-cell therapy has demonstrated promising outcomes in certain terminally ill patients with cancer, yet access to this treatment remains limited in LMICs, including Nepal.The Center for Regenerative Medicine in Nepal has initiated efforts to make CAR-T cell therapy accessible to patients with cancer at a substantially reduced cost. …”
Get full text

Venetoclax in combination with chidamide and azacitidine for the treatment of relapsed/refractory B-cell acute lymphoblastic leukemia with the MLL-AF4 gene: a case report and liter... by Xuelian Jin, Zhigang Liu, Yu Wu, Jie Ji

“…Following two VCA courses, he received chimeric antigen receptor T-cell therapy, which led to complete metabolic remission and improved prognosis. …”
Get full text

CAR-T CELL THERAPY IN B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA by Ugo Testa, Simona Sica, Elvira Pelosi, Germana Castelli, Giuseppe Leone

“…Studies carried out in the last two decades have shown that autologous T cells engineered to express a chimeric antigen receptor (CAR-T) represent an effective technique for treating these patients. …”
Get full text

Innovative immunotherapies and emerging treatments in type 1 diabetes management by Malek Zarei, Mohammad Abbas Sheikholeslami, Masoud Mozaffari, Yassar Mortada

“…Novel approaches, such as Chimeric Antigen Receptor (CAR)–Tregs therapy and JAK-STAT pathway inhibition, represent exciting areas of ongoing research. …”
Get full text

Hotspots evolution and frontiers of immunotherapy for the treatment of acute myeloid leukemia: A bibliometric analysis by Nana Zhe, Qiang Li, Nanqu Huang, Hang Li, Hongyun Chen, Pinwei Zhu

“…The current research hotspots of AML immunotherapy included chimeric antigen receptor-T-cell therapy, antibody-based immunotherapies, immune checkpoint blockade, and combination therapy, highlighting the key aspects of immunotherapy for AML treatment and providing comprehensive insights into the research status and advances in this field. …”
Get full text